|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
US5156965A
(en)
|
1983-11-29 |
1992-10-20 |
Igen, Inc. |
Catalytic antibodies
|
|
US5229272A
(en)
|
1989-04-25 |
1993-07-20 |
Igen, Inc. |
Catalytic antibody components
|
|
US5030717A
(en)
|
1986-09-17 |
1991-07-09 |
Scripps Clinic And Research Foundation |
Antibodies which catalyze hydrolysis of ester bonds
|
|
US5126258A
(en)
|
1984-09-07 |
1992-06-30 |
Scripps Clinic And Research Foundation |
Molecules with antibody combining sites that exhibit catalytic properties
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
US5851527A
(en)
|
1988-04-18 |
1998-12-22 |
Immunomedics, Inc. |
Method for antibody targeting of therapeutic agents
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5858728A
(en)
|
1991-03-13 |
1999-01-12 |
Common Services Agency |
Monoclonal antibody against LPS core
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5436153A
(en)
|
1992-12-02 |
1995-07-25 |
Sprecher; Cindy A. |
Human amyloid protein precursor homolog and Kunitz-type inhibitor
|
|
WO1994012637A2
(en)
|
1992-12-02 |
1994-06-09 |
Zymogenetics, Inc. |
Novel human amyloid protein precursor homologue and kunitz-type inhibitors
|
|
AU6942394A
(en)
|
1993-04-23 |
1994-11-21 |
Igen, Inc. |
Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies
|
|
US5602021A
(en)
|
1994-12-29 |
1997-02-11 |
Catalytic Antibodies, Inc. |
Method for generating proteolytic enzymes specific against a selected peptide sequence
|
|
US5585108A
(en)
|
1994-12-30 |
1996-12-17 |
Nanosystems L.L.C. |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US6372205B1
(en)
|
1997-06-11 |
2002-04-16 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
|
|
IT1293511B1
(it)
|
1997-07-30 |
1999-03-01 |
Gentili Ist Spa |
Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
|
|
JP2002509158A
(ja)
|
1998-01-15 |
2002-03-26 |
センター・フォー・モレキュラー・メディシン・アンド・イムノロジー |
アーム付きリガンドの送達向上のための抗体と受容体ターゲティング部分
|
|
US6703488B1
(en)
|
1998-01-15 |
2004-03-09 |
Center For Molecular Medicine And Immunology |
Antibody/receptor targeting moiety for enhanced delivery of armed ligand
|
|
US6855804B2
(en)
|
1998-03-23 |
2005-02-15 |
Board Of Regents, The University Of Texas System |
Covalently reactive transition state analogs and methods of use thereof
|
|
US6235714B1
(en)
|
1998-03-23 |
2001-05-22 |
Sudhir Paul |
Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
|
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
|
WO2000022110A2
(en)
|
1998-10-09 |
2000-04-20 |
President And Fellows Of Harvard College |
Targeted proteolysis by recruitment to ubiquitin protein ligases
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
AU1490801A
(en)
|
1999-11-15 |
2001-05-30 |
University Of Southern California |
Targeted delivery of therapeutic and diagnostic moieties
|
|
DE10034607A1
(de)
|
2000-07-20 |
2002-02-07 |
Gundram Jung |
Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
|
|
WO2002020740A2
(en)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20070258987A1
(en)
|
2000-11-28 |
2007-11-08 |
Seattle Genetics, Inc. |
Recombinant Anti-Cd30 Antibodies and Uses Thereof
|
|
US7431923B2
(en)
|
2005-01-03 |
2008-10-07 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
CA2462883A1
(en)
|
2001-10-12 |
2003-04-17 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
|
EP1474109B1
(en)
|
2001-12-21 |
2010-08-25 |
Alcon, Inc. |
Use of synthetic inorganic nanoparticles as carriers for ophthalmic drugs
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
CA2529659A1
(en)
|
2003-06-18 |
2004-12-29 |
Ulrich Haupts |
Engineered proteolytic enzyme with altered specificity determining regions
|
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
US7371539B2
(en)
|
2003-12-03 |
2008-05-13 |
President And Fellows Of Harvard College |
Targeted polypeptide degradation
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
AR048098A1
(es)
|
2004-03-15 |
2006-03-29 |
Wyeth Corp |
Conjugados de caliqueamicina
|
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
JP5307708B2
(ja)
|
2006-06-02 |
2013-10-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒトｉｌ−６受容体に対する高親和性抗体
|
|
US20080089891A1
(en)
|
2006-07-26 |
2008-04-17 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
|
WO2008014404A2
(en)
|
2006-07-26 |
2008-01-31 |
The University Of Chicago |
Receptor-mediated delivery : compositions and methods
|
|
US8350011B2
(en)
|
2006-08-04 |
2013-01-08 |
Medimmune Limited |
Antibodies to ErbB2
|
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
|
WO2008122039A2
(en)
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
|
EP2167963B1
(en)
|
2007-05-23 |
2019-04-17 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
US20090258005A1
(en)
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
EP2150617B1
(en)
|
2007-06-04 |
2014-10-22 |
Regeneron Pharmaceuticals, Inc. |
Enhanced expression and stability regions
|
|
KR20100058509A
(ko)
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
|
US8420620B2
(en)
|
2008-01-24 |
2013-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Induced internalization of surface receptors
|
|
SG189817A1
(en)
|
2008-04-30 |
2013-05-31 |
Immunogen Inc |
Potent conjugates and hydrophilic linkers
|
|
AU2009275358C1
(en)
|
2008-07-21 |
2015-09-24 |
Polytherics Limited |
Novel reagents and method for conjugating biological molecules
|
|
CN102164960A
(zh)
|
2008-09-26 |
2011-08-24 |
罗氏格黎卡特股份公司 |
双特异性抗-egfr/抗-igf-1r抗体
|
|
MX2011010166A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
|
EP2241576A1
(en)
|
2009-04-17 |
2010-10-20 |
Trion Pharma Gmbh |
Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
|
|
MY192182A
(en)
|
2009-06-26 |
2022-08-04 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
|
AU2010283632B2
(en)
|
2009-08-10 |
2016-08-25 |
Ucl Business Plc |
Reversible covalent linkage of functional molecules
|
|
SMT202600080T1
(it)
|
2010-02-08 |
2026-03-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
SI2528625T1
(sl)
|
2010-04-15 |
2013-11-29 |
Spirogen Sarl |
Pirolobenzodiazepini in njihovi konjugati
|
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
US20130244905A1
(en)
|
2010-07-06 |
2013-09-19 |
Ed Grabczyk |
Reporter for RNA Polymerase II Termination
|
|
RU2013150331A
(ru)
|
2011-04-20 |
2015-05-27 |
Рош Гликарт Аг |
СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
CN103796678B
(zh)
|
2011-04-20 |
2018-02-27 |
健玛保 |
针对her2的双特异性抗体
|
|
CN110078789A
(zh)
|
2011-05-27 |
2019-08-02 |
Ambrx 公司 |
含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
CN103997893B
(zh)
|
2011-10-14 |
2019-04-12 |
西雅图基因公司 |
吡咯并苯并二氮杂卓和靶向结合物
|
|
EP2751111B1
(en)
|
2011-10-14 |
2017-04-26 |
MedImmune Limited |
Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
|
|
BR112014009070B1
(pt)
|
2011-10-14 |
2021-11-23 |
Medimmune Limited |
Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
|
|
CA2850373C
(en)
|
2011-10-14 |
2019-07-16 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
|
RU2014124984A
(ru)
|
2011-12-05 |
2016-01-27 |
Идженика Биотерапьютикс, Инк. |
Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
|
|
EP2825553B1
(en)
|
2012-03-14 |
2018-07-25 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules and uses thereof
|
|
KR20150008171A
(ko)
|
2012-05-10 |
2015-01-21 |
자임워크스 인코포레이티드 |
단일군 일가 항체 구조물 및 그의 용도
|
|
CN105142672B
(zh)
|
2012-10-23 |
2019-04-05 |
西纳福克斯股份有限公司 |
经修饰的抗体、抗体-缀合物及其制备方法
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
JP6847388B2
(ja)
|
2013-03-15 |
2021-03-31 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
生物活性分子、そのコンジュゲート、及び治療用途
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
TWI641620B
(zh)
|
2013-08-21 |
2018-11-21 |
再生元醫藥公司 |
抗－ｐｒｌｒ抗體及其用途
|
|
BR112016004023A2
(pt)
|
2013-08-26 |
2022-11-16 |
Regeneron Pharma |
Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
|
|
WO2016065319A1
(en)
|
2014-10-24 |
2016-04-28 |
Shire Human Genetic Therapies, Inc. |
Lysosomal targeting of enzymes, and uses thereof
|
|
MA41022A
(fr)
|
2014-11-24 |
2017-10-03 |
Shire Human Genetic Therapies |
Ciblage lysosomial et utilisations correspondantes
|
|
BR112017020149A8
(pt)
|
2015-03-27 |
2023-05-02 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
|
|
IL296285A
(en)
*
|
2015-07-06 |
2022-11-01 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
BR112018014759B1
(pt)
|
2016-01-25 |
2024-02-27 |
Regeneron Pharmaceuticals, Inc |
Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
|
|
KR20260018979A
(ko)
*
|
2016-02-05 |
2026-02-09 |
젠맵 에이/에스 |
개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
|
|
EP3448891A1
(en)
*
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|